The change to personalized treatment based on appropriate patient selection has been advanced by the identification of epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements in non-small cell lung cancer (NSCLC) (2). Here, ALK is linked to non-small cell lung carcinoma.